High Throughput Screening (HTS): A Global Strategic Business Report
San Jose, CA (PRWEB) June 06, 2011
High Throughout Screening today accounts for a significant 35% share in the global drug discovery technologies market. The growing importance is primarily attributed to the increasing usage of highly advanced techniques such as robotics and cell based assays in parallel compound screening. Utilization of effective screening modes and the need for speeding up the entire process of drug discovery ranks high on the agenda of companies involved in drug discovery. There is a constant need to keep abreast of technology upgradations and adopt accurate, rapid and cost effective HTS instrumentation in order to stay competitive in the marketplace. Currently, major necessities include diversity in chemical libraries, ease of integrating innovative technologies and flexibility in instrumentation.
The field of HTS is a competitive and dynamic marketplace with open technology transfers and information sharing among competing companies. Pharmaceutical companies continuously vie to be the first to market a new drug, with wafer thin margin between success and failures in new drug discoveries. This is primarily where high throughput screening steps in, by significantly reducing the time-to-market of new drugs. Currently, the US is sitting pretty at the top as the largest market for HTS, mainly attributed to the presence of major biotechnology and pharmaceutical companies.
Drug Discovery firms are investing huge sums into HTS technology, providing a tremendous boost to the market and leading to simultaneous development of robust computational hardware and software. Miniaturization, use of primary or stem cells, increasing compound diversity and establishment of new joint initiatives for supporting HTS are expected to be important links fulfilling unmet HTS challenges. Biochemical assays are witnessing increasing usage for compound identification, while high-content screening (HCS), an extended version of HTS is also gaining traction. Integration of bioinformatics and robotics generated considerable time and cost savings by discarding manual interventions and ensuring precise and timely results.
Lately, drug discovery companies have been outsourcing HTS activities as a means towards cost saving. The outsourcing trend has since gathered momentum and currently accounts for about 50% share in the overall drug development expenditure. The recent recession and the need for cost cutting further bolstered the HTS outsourcing market. Outsourcing reduces both the timeline and associated costs of drug development, while also making innovative technologies and additional drug entities easily accessible.
The US represents the largest worldwide market, as stated by the new research report on High Throughput Screening. Active stimulus by the US government and research institutes in the form of financial, infrastructure and technological support played a major hand in promotion and proliferation of the technology in the region. The market is forecast to continue the healthy trend, growing at a robust pace in the long term.
Although Europe does not enjoy the same market standing as the US market, HTS technologies have a wide acceptance in the European region with biotech and pharmaceutical companies making HTS an integral part of their drug discovery endeavors. Backed by growth from France, Italy, UK, Germany, Sweden and Switzerland among others, Europe is slated to progress at the highest CAGR of about 12% through 2017.
Key market participants in the report include Agilent Technologies Inc, BIOCIUS Life Sciences, Inc, Aurora Biomed Inc, Axxam SpA, Beckman Coulter, Inc, BioFocus DPI Ltd, BMG LABTECH GmbH, Caliper Life Sciences, Corning Inc, DiscoveRx Corporation, EVOTEC BioSystems, ForteBio, Inc, Genedata AG, IntelliCyt Corporation, Luminex Corporation, Life Technologies Corporation, MatriCal Bioscience, PerkinElmer Inc, Roche Applied Sciences and Sigma-Aldrich Corporation.
The research report titled “High Throughput Screening (HTS): A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of industry and product overview, current market trends & issues, HTS technologies, drug discovery market, technological developments, recent industry activity and profiles of market players worldwide. Market analytics and overview is provided in value (US$) terms for major geographic markets such as US, Canada, Japan, Europe and Rest of World. The study also provides historic data for an insight into market evolution over the period 2003 through 2008.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/High_Throughput_Screening_HTS_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1300 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/